

## **MiMedx Group to Present at the BIOX; Noble Financial Capital Markets' Life Sciences Exposition**

September 18, 2012 9:05 AM ET

**PRESS RELEASE Contact: Michael Senken  
Phone: (678) 384-6720**

### **MiMedx Group to Present at the BIOX; Noble Financial Capital Markets' Life Sciences Exposition**

**KENNESAW, Georgia, September 18, 2012** (PR Newswire) – MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today that it will be presenting Monday, September 24, 2012 at the BIOX; Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus. Frank Burrows, Vice President of Corporate Strategy is scheduled to participate on a panel entitled "Regenerative Medicine-Tissue Engineering and Biomaterials."

#### **About the Company**

MiMedx<sup>®</sup> is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "***Innovations in Regenerative Biomaterials***" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix<sup>®</sup> and CollaFix<sup>™</sup>, and our tissue technologies, AmnioFix<sup>®</sup> and EpiFix<sup>®</sup>. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion<sup>®</sup> Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 90,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.